Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi (MGX) Accumulated Depreciation (2023 - 2025)

Metagenomi (MGX) has disclosed Accumulated Depreciation for 2 consecutive years, with $16.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Accumulated Depreciation changed N/A to $16.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $16.0 million, a N/A change, with the full-year FY2025 number at $16.0 million, changed N/A from a year prior.
  • Accumulated Depreciation was $16.0 million for Q4 2025 at Metagenomi, up from $6.4 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $16.0 million in Q4 2025 to a low of $6.4 million in Q4 2023.